Status:

COMPLETED

Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial

Lead Sponsor:

Shahid Beheshti University of Medical Sciences

Conditions:

Retinal Disease

Eligibility:

All Genders

40+ years

Phase:

PHASE3

Brief Summary

In this study we intend to evaluate the outcome of intravitreal avastin on improving the visual acuity and macular edema and late complications of BRVO like NVD and NVE

Detailed Description

After diabetic retinopathy, vein occlusion is the second most common retinovascular disease. According to BVO study the only effective management of it is macular photocoagulation for macular thickeni...

Eligibility Criteria

Inclusion

  • patients with acute BRVO with less than three month duration

Exclusion

  • vision less than 20/320 and vison more than 20/50
  • duration more than 3 months
  • history of glaucoma and diabetic retinopathy
  • any media opacity that prevent funduscopy

Key Trial Info

Start Date :

August 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2008

Estimated Enrollment :

82 Patients enrolled

Trial Details

Trial ID

NCT00370851

Start Date

August 1 2006

End Date

June 1 2008

Last Update

November 25 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Siamak Moradian, MD

Tehran, Tehran Province, Iran, 16666

Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial | DecenTrialz